Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408425 | 0.87 | NPC1 (0.51) | DDAH1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL13481227 | 0.84 | ALDH1A1 (0.60) | DDAH1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL8150859 | 0.82 | DAGLA (0.54) | DDAH1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL7528716 | 0.81 | ALDH1A1 (0.53) | DDAH1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL5627161 | 0.80 | RAB9A (0.56) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL291450 | 0.80 | ALDH1A1 (0.59) | DDAH1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL29539476 | 0.79 | ALDH1A1 (0.81) | DDAH1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL1086985 | 0.79 | ALDH1A1 (0.81) | DDAH1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL19119423 | 0.79 | ALDH1A1 (0.63) | DDAH1KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL1086983 | 0.79 | ALDH1A1 (0.81) | DDAH1KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1167375-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5616586-A | Tricyclic quinoxalinediones | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| WO-1996040141-A1 | 4,5-BRIDGED QUINOXALINEDIONES AND QUINOLONES AND THE USE THEREOF AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0642508-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993008188-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | DDAH1 1363/4885KDM4E 1568/4885ALDH1A1 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.